Anti-inflammatory drug approved for use after cataract surgery

Article

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

Yellox, owned by CROMA, is to be administered twice daily as an ocular NSAID in adult patients after undergoing cataract surgery. Otherwise known as, Yellox (bromfenac sodium) targets the COX-2 enzyme- one of the prime causes of prostaglandin production and ocular inflammation. The solution penetrates through the cornea and ocular tissues to treat ocular inflammation.

CROMA will collaborate with Bausch+Lomb to promote the ophthalmic solution in Austria, France, Spain, Poland and Romania. Bausch+Lomb will manage promotions in the remaining EU countries.

Chief Medical Officer of Bausch+Lomb, Dr Cal Roberts, said: “Yellox is very promising for cataract surgery patients. The drug helps meet the unmet needs of both patients and physicians alike across a number of European markets, offering them a new choice to treat post-operative ocular inflammation following cataract extraction.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.